Four intervention pages — a drug for weight (Semaglutide for Cardiovascular Risk in Obesity), a drug for lipids (Statins for Primary Prevention and the Power of Zero CAC), lifestyle weight loss (Does Weight Loss Reduce Cardiovascular Events), and blood-pressure lowering (Blood Pressure Lowering and Cardiovascular Events) — answer the same decision question, and the pattern is on none of them individually. Assembled, they make one claim that is a decision-change: for a genuinely low-risk primary-prevention person, no cardiometabolic intervention the wiki holds delivers a large absolute reduction in hard cardiovascular events. The first three are unproven there or below the action threshold; the fourth, BP-lowering, is the sharp test — its relative benefit is proven in primary prevention, and the claim survives only because a proven relative effect on a low absolute baseline is still a small absolute gain. A fifth intervention, aspirin, is treated below as a distinct case: it is not one of the four sharing that question, and it reaches the same ceiling by a different mechanism — a proven relative benefit exactly cancelled by a proven bleeding harm — so it sharpens rather than repeats the pattern.
The four, on the one question
| Intervention | Hard-CV-outcome evidence, and where it applies | For a low-risk / primary-prevention person |
|---|---|---|
| Semaglutide (drug→weight) | MACE «hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90» — but only in secondary prevention (established CVD); primary prevention «were not studied» (Lincoff et al., 2023) | Unproven. Weight + surrogates transfer; the CV-event benefit does not |
| Statin (drug→lipids) | Efficacy real and roughly constant per mmol/L; USPSTF acts only at ≥7.5–10% 10-year risk because benefit is proportional to risk; CAC=0 lifts NNT to 64 vs 28 (Nasir et al., 2015) | Small, below the threshold. USPSTF: below ~7.5% risk, not a candidate at all (US Preventive Services Task Force, 2022) |
| Lifestyle weight loss | Look AHEAD «hazard ratio 0.95; 95% CI 0.83 to 1.09» — null in T2D despite real weight loss and a large CRP reduction (~42-45% with intensive lifestyle on statins, vs 14-21% usual care) (Look AHEAD Research Group, 2013) (Belalcazar et al., 2013) | Unproven / null via this route |
| BP-lowering (drug) | BPLTTC IPD: HR 0.91 (0.89-0.94) even without prior CVD, no heterogeneity down to <120 mmHg (Blood Pressure Lowering Treatment Trialists Collaboration, 2021) — relative benefit proven in primary prevention | Proven relative, small absolute. ~10% per 5 mmHg on a low baseline is a small absolute gain; the authors say treat on absolute risk |
Each per-page cross-source comparison already carries its own parameter table; this page configures those settled findings, it does not re-derive a magnitude.
A fifth intervention sharpens the pattern — aspirin (added 2026-08-20)
Aspirin (Aspirin for Primary Prevention of Cardiovascular Disease) is the sharpest case because it fails the low-risk person on a different mechanism than the four above. The other four are unproven or below threshold in primary prevention; aspirin’s relative CV benefit is proven there (composite HR 0.89, 95% CrI 0.84-0.94) — yet it still delivers no net gain, because a matched, also-proven bleeding harm cancels it. On the largest trial-level MA (13 RCTs, 164 225 people) the composite-CV ARR is 0.41% (0.23-0.59) against a major-bleeding ARI of 0.47% (0.34-0.62) — NNT 241 vs NNH 210 — so the harm arm marginally exceeds the benefit, with no mortality benefit (Zheng & Roddick, 2019).
It also stress-tests shared mechanism #1 below (absolute benefit scales with baseline risk). For the other four, raising baseline risk is the escape hatch — a proven relative effect buys more absolute benefit in a higher-risk person. Aspirin closes that hatch: the bleeding harm co-travels with cardiovascular risk, so both arms scale together and the net stays a wash-to-negative in the low-risk, high-risk, and diabetes strata alike (bleeding ARI >= CV ARR in every one) (Zheng & Roddick, 2019). So for aspirin, even a higher-risk person is not rescued by route-(a) — a stronger conclusion than the ceiling finding needs, and one the other four do not reach.
Why they converge — three shared mechanisms, not a coincidence
- Absolute benefit scales with baseline risk (Baseline Risk and the Relative-Absolute Split). A constant relative effect on a low baseline is a small absolute effect. This is why USPSTF sets a risk threshold, why SELECT’s benefit would shrink ~5-fold at a primary-prevention baseline, and why a CAC=0 person’s statin NNT balloons. The machinery is identical across all three.
- The hard-outcome trials were run where the events are — in secondary prevention or high-risk populations, because that is where a trial can accrue events. So the evidence that exists is systematically about people at higher risk than the low-risk person asking. This is a structural feature of the evidence base, not a property of the drugs.
- Surrogate improvement does not carry the outcome (Surrogate Outcomes; The Certainty-Importance Inversion). Look AHEAD is the worked case: weight, HbA1c, fitness, blood pressure and CRP all moved the right way and the events did not follow. A good-looking risk-factor profile after an intervention is not evidence of an averted event. The dietary instance is the same shape: reducing saturated fat reliably lowers LDL, yet whether that lowers events is genuinely contested (Does Reducing Saturated Fat Reduce Cardiovascular Events) — the surrogate signal (LDL) is firmer than the outcome evidence it stands in for.
The largest levers are missing from the table — because their evidence is observational
The obvious objection to a ceiling finding is “but exercise.” It is worth answering, because the answer sharpens the ceiling rather than breaking it. The levers with the largest associations to hard outcomes are not the four above — they are activity and fitness, and they are absent from the proven-lever table on purpose:
- Aerobic activity: all-cause HR ~0.34 at the top of the dose-response (Physical Activity Dose and Mortality) — the single largest association the vault holds, dwarfing every RCT-proven lever here.
- Cardiorespiratory fitness: RR 0.87 per 1-MET (Cardiorespiratory Fitness and Mortality).
- Muscle-strengthening: all-cause RR 0.85 (Muscle-Strengthening Activity and Mortality).
They are absent because the evidence is a different, weaker kind. All three are observational — no RCT randomizes a lifetime of activity or fitness onto hard outcomes — so they carry the confounding and reverse-causation load the four RCT levers were designed to escape (the healthy-user and sick-quitter signatures; cf. The U-Shaped Association Artifact). This is a distinction of evidence type, not a magnitude contrast: you cannot set HR 0.34 (observational, all-cause) beside HR 0.80 (RCT, MACE, secondary prevention) as commensurable — which is exactly why activity is a predictor here, not a proven causal lever.
The sharpened ceiling: it is not that no large lever exists. It is that the proven levers are small-for-low-risk, and the large lever (activity/fitness) is the one whose causal effect on hard outcomes is structurally unprovable by RCT. So the low-risk person’s honest position is unchanged — no proven large CV-event lever — even after the biggest association in the vault is on the table.
The decision-change — this is a ceiling finding
This is Layer 1 - Ranking Interventions for a Stratum’s the ceiling is itself a finding made concrete for cardiovascular events in a low-risk person: the search for a large, proven CV-event lever comes up empty across drug and lifestyle routes alike, and reporting that is a result, not a failure. It licenses a low-risk person to stop optimizing for a heart-attack reduction that the evidence does not promise them — and to pursue these interventions, if at all, for the outcomes they do move (weight, glycemia, diabetes prevention, MASLD, function, and — for higher-risk people — events).
Three things this does NOT say, each a guard against over-reading:
- Not these interventions do not work. They work where risk is high enough (SELECT in secondary prevention; statins above threshold) and on non-CV outcomes everywhere. The claim is scoped to hard CV events in a low-risk person.
- Not surrogates are worthless. They are the reason to act on many other outcomes, and they raise prior plausibility — they just are not proof of an averted event.
- Not a claim about high-risk people. For established CVD, high 10-year risk, or a high CAC, the same machinery runs the other way: absolute benefit is large and the interventions are strongly indicated. The pattern is a statement about the low-risk tail, where most of the wiki’s healthy strata sit.
What tested it — and why the test sharpened rather than broke it
BP-lowering was the candidate refutation, and it is instructive that it refined the claim instead. Unlike the other three, its relative hard-outcome benefit is directly proven in primary prevention (BPLTTC HR 0.91 without prior CVD, no heterogeneity across baseline BP). Had the synthesis claimed no intervention has a proven relative effect in primary prevention, BP-lowering would have broken it. But the claim is about large absolute benefit for a low-risk person, and there BP-lowering lands exactly where the mechanism predicts: the paper’s own decision rule is treat on absolute cardiovascular risk, not the blood-pressure number, so a proven ~10%-per-5-mmHg relative effect still buys little for someone at low absolute risk. The one intervention that could speak to primary prevention confirmed mechanism 1 rather than escaping it.
PREDIMED is the second confirming test — a HIGH-risk contrast, not a counterexample. A dietary (Estruch et al., 2018) pattern (Mediterranean diet, energy-unrestricted) cut CV events ~30% (HR 0.70) with a real absolute benefit of ~1.7-2.1 percentage points over 5 years (Mediterranean Diet and Cardiovascular Events). That looks like a lifestyle intervention with a proven hard-outcome effect — but it lands exactly where the mechanism predicts, because its population was high absolute risk (~49% T2D, ~82% hypertensive), and its authors say outright that generalization «to persons at lower risk requires further research». Like BP-lowering, it refines the ceiling: an intervention can buy hard-outcome benefit where baseline risk is high; it says nothing about the low-risk person, where the absolute benefit of the same relative effect shrinks toward the mechanism-1 floor. (And PREDIMED’s all-cause mortality was null over 4.8 yr, so even at high risk the event benefit did not extend to death in-window.)
REDUCE-IT is the third confirming test — and the only one that shows mechanism 1 INSIDE a single trial
[2026-08-04]. A lipid-lever drug (icosapent ethyl 4 g/day) cut the primary CV composite by 25% in a
high-risk statin-treated, high-triglyceride population (NNT 21 overall; NNT ~16 in the
established-CVD arm) (Bhatt et al., 2019) — again exactly where a
trial can accrue events. The sharp part is its own two strata: the lower-risk primary-prevention arm
(DM + risk factor, event rate 13.6%) was attenuated to HR 0.88 (0.70-1.10), CI crossing 1, ARR ~1.4 pp,
versus the secondary-prevention arm’s HR 0.73 / ARR 6.2 pp (Bhatt et al., 2019). So the one trial displays the whole pattern — proven where risk is high, fading toward the
floor where it is low — and it does not supply a low-risk lever. (Bound: it is a prescription drug in a
selected hypertriglyceridemic stratum, and its mineral-oil comparator is contested, so it does not even
speak to the general low-risk person.) -> Baseline Risk and the Relative-Absolute Split.
(inferred from Bhatt et al., 2019)
preDIVA is a fourth confirming test — a lifestyle/vascular-care route, but a WEAKER instance whose null
is over-determined [2026-08-07]. preDIVA (Moll van Charante 2016) delivered 6.7 yr of nurse-led
multidomain vascular care (lifestyle advice + BP/lipid/glucose drug optimisation) to 3526 unselected
community-dwelling elderly — and found null on incident cardiovascular disease (HR 1.06, 0.86-1.31),
all-cause mortality (HR 0.98, 0.80-1.18), and dementia (HR 0.92)
(van Charante et al., 2016). The authors give
two reasons, and the FIRST is not baseline risk: «the contrast between study groups in cardiovascular
risk reduction was relatively small … the intensity of the vascular care … might have been
insufficient», then «this absence of effect might have been caused by modest baseline cardiovascular risks
and high standards of usual care» (van Charante et al., 2016). The small-contrast reason partly confounds the baseline-risk test: the achieved
systolic contrast was only -2.06 mm Hg, which through this page’s BPLTTC transmission (~HR 0.91 per
5 mmHg) predicts HR ~0.96 on CV events — undetectable at any baseline risk. So preDIVA is a
weaker mechanism-1 instance than BPLTTC/PREDIMED/REDUCE-IT (which achieved real relative effects and
still faded at low risk, cleanly isolating baseline risk); its near-zero contrast means it confirms only
the broad thesis — no proven large hard-CV lever in a not-high-risk population — not a clean
baseline-risk demonstration. Still directionally consistent: a well-managed, unselected elderly cohort is
exactly where both a thin contrast and a low absolute risk conspire toward null. (Convergent single-source
confirmation of the held thesis, not an independent-backing claim — no [E-independent].)
(inferred from van Charante et al., 2016)
WHI is a fifth confirming test — a large dietary-pattern RCT in a not-high-risk population, but a
WEAKER instance for the same reason as preDIVA [2026-08-25]. The Women’s Health Initiative Dietary
Modification Trial randomized 48,835 postmenopausal women (only 3.4% with baseline CVD — a
primary-prevention population) to a low-fat pattern for a mean 8.1 years and found null on CHD (HR
0.97, 0.90-1.06), stroke (1.02, 0.90-1.15), and CVD (0.98, 0.92-1.05)
(Howard et al., 2006). This is exactly the cell the
page names — a diet-pattern intervention that does not deliver a large hard-CV benefit in a not-high-risk
population. But like preDIVA its null is over-determined, so it confirms only the broad thesis, not a
clean baseline-risk demonstration: the achieved between-arm fat separation was only ~8.2%E («about 70%
of de- sign assumptions»), giving «a projected power of only approximately 40%» for an LDL change the
authors predicted would «produce only a small (2%- 4%) decrease in CVD risk»
(Howard et al., 2006) — and it tested the wrong
exposure (total-fat->carbohydrate, not the protective-food pattern the guidelines recommend). So it is
directionally consistent — a diluted contrast plus a low absolute risk conspiring toward null — but a
weaker mechanism-instance than the trials that achieved a real relative effect and still faded at low
risk. Details on Low-Fat Dietary Pattern and Cardiovascular Disease. (Convergent single-source
confirmation of the held thesis, not independent backing — no [E-independent].)
(inferred from Howard et al., 2006)
What still would break it: a primary-prevention cardiovascular-outcome trial of an obesity drug (does not yet exist), a weight-loss-mortality review finding benefit beyond T2D, a CAC-randomized statin trial with benefit at CAC=0, or a dietary-pattern RCT showing hard-outcome benefit in a genuinely LOW-risk population — any would move a large-absolute-at-low-risk cell from unproven toward proven. Until then the pattern holds, and its confidence is high: six intervention classes across drug, diet-pattern and lifestyle — including the ones with the strongest primary-prevention evidence, and one (REDUCE-IT) that displays the baseline-risk gradient within a single trial — all land in the same place by the same mechanism. Aspirin adds a seventh class that reaches the same place by a different route — a proven relative benefit cancelled by a matched, also-proven bleeding harm — so the ceiling holds even where a low-risk primary-prevention benefit is demonstrable, which strengthens rather than dilutes the finding.